Search Results - "DRAPPATZ, Jan"

Immunotherapy associated central nervous system complications in primary brain tumors by Mantica, Megan, Drappatz, Jan

“…Advances clarifying the genetics and function of the immune system within the central nervous system (CNS) and brain tumor microenvironment have led to…”
Get full text

Antiangiogenic therapies for high-grade glioma by Wen, Patrick Y, Norden, Andrew D, Drappatz, Jan

“…High-grade gliomas are highly vascularized tumors that represent attractive targets for antiangiogenic therapies. In this article, Norden et al . discuss the…”
Get full text

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma by Kaley, Thomas J, Wen, Patrick, Schiff, David, Ligon, Keith, Haidar, Sam, Karimi, Sasan, Lassman, Andrew B, Nolan, Craig P, DeAngelis, Lisa M, Gavrilovic, Igor, Norden, Andrew, Drappatz, Jan, Lee, Eudocia Quant, Purow, Benjamin, Plotkin, Scott R, Batchelor, Tracy, Abrey, Lauren E, Omuro, Antonio

“…No proven effective medical therapy for surgery and radiation-refractory meningiomas exists. Sunitinib malate (SU011248) is a small-molecule tyrosine kinase…”
Get full text

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma by BATCHELOR, Tracy T, DUDA, Dan G, LOUIS, David N, COHEN, Kenneth S, CHEA, Houng, EXARHOPOULOS, Alexis, LOEFFLER, Jay S, MOSES, Marsha A, IVY, Percy, SORENSEN, A. Gregory, WEN, Patrick Y, JAIN, Rakesh K, DI TOMASO, Emmanuelle, ANCUKIEWICZ, Marek, PLOTKIN, Scott R, GERSTNER, Elizabeth, EICHLER, April F, DRAPPATZ, Jan, HOCHBERG, Fred H, BENNER, Thomas

“…Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of…”
Get full text

Novel anti-angiogenic therapies for malignant gliomas by Norden, Andrew D, MD, Drappatz, Jan, MD, Wen, Patrick Y, MD

“…Summary Background Despite optimum treatment with surgery, radiation therapy, and chemotherapy, most patients with malignant glioma have a poor prognosis…”
Get full text

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients by Batchelor, Tracy T., Sorensen, A. Gregory, di Tomaso, Emmanuelle, Zhang, Wei-Ting, Duda, Dan G., Cohen, Kenneth S., Kozak, Kevin R., Cahill, Daniel P., Chen, Poe-Jou, Zhu, Mingwang, Ancukiewicz, Marek, Mrugala, Maciej M., Plotkin, Scott, Drappatz, Jan, Louis, David N., Ivy, Percy, Scadden, David T., Benner, Thomas, Loeffler, Jay S., Wen, Patrick Y., Jain, Rakesh K.

“…Using MRI techniques, we show here that normalization of tumor vessels in recurrent glioblastoma patients by daily administration of AZD2171—an oral tyrosine…”
Get full text

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors by Vivanco, Igor, Robins, H Ian, Rohle, Daniel, Campos, Carl, Grommes, Christian, Nghiemphu, Phioanh Leia, Kubek, Sara, Oldrini, Barbara, Chheda, Milan G, Yannuzzi, Nicolas, Tao, Hui, Zhu, Shaojun, Iwanami, Akio, Kuga, Daisuke, Dang, Julie, Pedraza, Alicia, Brennan, Cameron W, Heguy, Adriana, Liau, Linda M, Lieberman, Frank, Yung, W K Alfred, Gilbert, Mark R, Reardon, David A, Drappatz, Jan, Wen, Patrick Y, Lamborn, Kathleen R, Chang, Susan M, Prados, Michael D, Fine, Howard A, Horvath, Steve, Wu, Nian, Lassman, Andrew B, DeAngelis, Lisa M, Yong, William H, Kuhn, John G, Mischel, Paul S, Mehta, Minesh P, Cloughesy, Timothy F, Mellinghoff, Ingo K

“…Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions in the extracellular (EC) domain. Unlike…”
Get more information

Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma by Rubenstein, James L., Li, Jing, Chen, Lingjing, Advani, Ranjana, Drappatz, Jan, Gerstner, Elizabeth, Batchelor, Tracy, Krouwer, Hendrikus, Hwang, James, Auerback, Glenna, Kadoch, Cigall, Lowell, Clifford, Munster, Pamela, Cha, Soonmee, Shuman, Marc A., Damon, Lloyd E.

“…Recurrent CNS lymphoma continues to be associated with poor outcomes in the rituximab era. Although IV rituximab mediates superior disease control of systemic…”
Get full text

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma by Norden, Andrew D, Ligon, Keith L, Hammond, Samantha N, Muzikansky, Alona, Reardon, David A, Kaley, Thomas J, Batchelor, Tracy T, Plotkin, Scott R, Raizer, Jeffrey J, Wong, Eric T, Drappatz, Jan, Lesser, Glenn J, Haidar, Sam, Beroukhim, Rameen, Lee, Eudocia Q, Doherty, Lisa, Lafrankie, Debra, Gaffey, Sarah C, Gerard, Mary, Smith, Katrina H, McCluskey, Christine, Phuphanich, Surasak, Wen, Patrick Y

“…OBJECTIVE:A subset of meningiomas recur after surgery and radiation therapy, but no medical therapy for recurrent meningioma has proven effective…”
Get full text

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab by Quant, Eudocia C, Norden, Andrew D, Drappatz, Jan, Muzikansky, Alona, Doherty, Lisa, Lafrankie, Debra, Ciampa, Abigail, Kesari, Santosh, Wen, Patrick Y

“…Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that has efficacy in recurrent malignant gliomas, particularly…”
Get full text

Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis by Horky, Laura L., Hsiao, Edward M., Weiss, Stephanie E., Drappatz, Jan, Gerbaudo, Victor H.

“…To study the ability of dual phase FDG-PET/CT imaging to accurately distinguish tumor versus necrosis in patients treated for brain metastases. 32 (22 female,…”
Get full text

Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults by Kesari, Santosh, Schiff, David, Drappatz, Jan, LaFrankie, Debra, Doherty, Lisa, Macklin, Eric A, Muzikansky, Alona, Santagata, Sandro, Ligon, Keith L, Norden, Andrew D, Ciampa, Abigail, Bradshaw, Joanna, Levy, Brenda, Radakovic, Gospova, Ramakrishna, Naren, Black, Peter M, Wen, Patrick Y

“…Purpose: Resistance to temozolomide chemotherapy is partly mediated by O 6 -methylguanine-DNA methlytransferase (MGMT). Protracted treatment with temozolomide…”
Get full text

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases by Garcia, Christine A, El-Ali, Alex, Rath, Tanya J, Contis, Lydia C, Gorantla, Vikram, Drappatz, Jan, Davar, Diwakar

“…PD-1 and CTLA-4 inhibitors are associated with several adverse events including a spectrum of immune-related adverse effects (irAEs). Neurologic irAEs are…”
Get full text

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma by Ellingson, Benjamin M, Aftab, Dana T, Schwab, Gisela M, Hessel, Colin, Harris, Robert J, Woodworth, Davis C, Leu, Kevin, Chakhoyan, Ararat, Raymond, Catalina, Drappatz, Jan, de Groot, John, Prados, Michael D, Reardon, David A, Schiff, David, Chamberlain, Marc, Mikkelsen, Tom, Desjardins, Annick, Holland, Jaymes, Ping, Jerry, Weitzman, Ron, Wen, Patrick Y, Cloughesy, Timothy F

“…Abstract Background To overcome challenges with traditional response assessment in anti-angiogenic agents, the current study uses T1 subtraction maps to…”
Get full text

Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic by Gatson, Na Tosha N, Barnholtz-Sloan, Jill, Drappatz, Jan, Henriksson, Roger, Hottinger, Andreas F, Hinoul, Piet, Kruchko, Carol, Puduvalli, Vinay K, Tran, David D, Wong, Eric T, Glas, Martin

“…The COVID-19 pandemic has placed excessive strain on health care systems and is especially evident in treatment decision-making for cancer patients…”
Get full text

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma by Schiff, David, Kesari, Santosh, de Groot, John, Mikkelsen, Tom, Drappatz, Jan, Coyle, Thomas, Fichtel, Lisa, Silver, Bruce, Walters, Ian, Reardon, David

“…Summary VEGF signaling through VEGFR-2 is the major factor in glioblastoma angiogenesis. CT-322, a pegylated protein engineered from the 10th type III human…”
Get full text

Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma by Nayak, Lakshmi, Abrey, Lauren E., Drappatz, Jan, Gilbert, Mark R., Reardon, David A., Wen, Patrick Y., Prados, Michael, Deangelis, Lisa M., Omuro, Antonio

“…We initiated a prospective multicenter phase II trial using rituximab and temozolomide in immunocompetent patients with progressive or recurrent primary…”
Get full text

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma by Norden, Andrew D., Drappatz, Jan, Muzikansky, Alona, David, Karly, Gerard, Mary, McNamara, M. Brenna, Phan, Phuong, Ross, Ainsley, Kesari, Santosh, Wen, Patrick Y.

“…Recent clinical trial results suggest that anti-angiogenic therapy may be effective against recurrent malignant glioma. Though these treatments prolong…”
Get full text

Psychometric evaluation of the Caregiver Needs Screen in neuro-oncology family caregivers by Boele, Florien, Terhorst, Lauren, Prince, Jennifer, Donovan, Heidi, Weimer, Jason, Lieberman, Frank, Drappatz, Jan, Sherwood, Paula

Get full text

Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma by Drappatz, Jan, M.D, Norden, Andrew D., M.D, Wong, Eric T., M.D, Doherty, Lisa M., MSN, LaFrankie, Debra C., RN, OCN, Ciampa, Abigail, MSN, Kesari, Santosh, M.D., Ph.D, Sceppa, Christine, BA, Gerard, Mary, BA, Phan, Phuong, BS, Schiff, David, M.D, Batchelor, Tracy T., M.D., M.P.H, Ligon, Keith L., M.D., Ph.D, Young, Geoffrey, M.D, Muzikansky, Alona, M.A, Weiss, Stephanie E., M.D, Wen, Patrick Y., M.D

“…Purpose Increasing evidence has suggested that angiogenesis inhibition might potentiate the effects of radiotherapy and chemotherapy in patients with…”
Get full text